Table 3.
Frequency of antibody response toward KRR1 and ZRF1 antigens in the sera of patients of different histological types of breast tumors in view of age∗.
| Antigen | The number of positive sera∗∗, n (%) | ||||||
|---|---|---|---|---|---|---|---|
| HD over 45 (n = 21) | HD under 45 (n = 35) | BC over 45 (n = 112) | MBC over 45 (n = 7) | IDC over 45 (n = 82) | ILC over 45 (n = 23) | FA under 45 (n = 20) | |
| ZRF1 | 1 (4,76) | 1 (2.86) | 28 (25,00) † | 1 (14,29) | 22 (26,83) † | 5 (21,74) | 2 (10,00) |
| Mean ± SD | 0,1513 ± 0,057 | 0,1446 ± 0,049 | 0,2242 ± 0,132 | 0,20534 ± 0,061 | 0,2383 ± 0,144 | 0,18 ± 0,084 | 0,1706 ± 0,094 |
| KRR1 | 0 (0) | 2 (5,71) | 23 (20,54) † | 1 (14,29) | 21 (25,61) † | 1 (7,14) | 0 (0) |
| Mean ± SD | 0,2288 ± 0,080 | 0,2403 ± 0,060 | 0,3246 + 0,080 | 0,2843 ± 0,072 | 0,3430 ± 0,077 | 0,2712 ± 0,068 | 0,1884 ± 0,054 |
Notes: ∗statistical analysis of frequency of antibody response was calculated between BC patients and healthy individuals cohorts over 45 years old and between FA and healthy individuals cohorts under 45 years old; ∗∗threshold: the mean plus 2 SD in the group of healthy donors; †Statistically significant difference compared to healthy donors' sera (P < 0.05). HD: healthy donors; BC: breast cancer (IDC + ILC + MBC); MBC: medullary breast carcinoma; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; FA: fibroadenoma.